Dementia in Parkinson disease -: A proton magnetic resonance spectroscopy study

被引:47
作者
Summerfield, C
Ansón, BG
Tolosa, E
Mercader, JM
Marti, MJ
Pastor, P
Junqué, C
机构
[1] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Psychiat & Clin Psychobiol, Barcelona, Spain
[2] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Inst Malalties Sistema Nervios, Dept Neurol,Hosp Clin, Barcelona, Spain
[3] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, CDI,Radiol Dept, Barcelona, Spain
关键词
D O I
10.1001/archneur.59.9.1415
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Magnetic resonance spectroscopy has been shown to be useful in differentiating idiopathic Parkinson disease (PD) from atypical parkinsonian syndromes such as progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration. Objective: To systematically investigate the utility of proton magnetic resonance spectroscopy in distinguishing between idiopathic PD with dementia (PDD) and without dementia. Design: Group comparisons and correlations of brain metabolites with clinical and neuropsychological variables. Patients and Methods: Metabolite concentrations were acquired from voxels localized to the basal ganglia and occipital cortex in 14 patients diagnosed as having idiopathic PDD, 12 patients with PD without dementia, and 13 matched control subjects. The 3 groups underwent clinical and. neuropsychological assessment. Results: In the occipital region, N-acetylaspartate levels were significantly reduced in the PDD group relative to the PD and control groups. N-acetylaspartate values correlated with neuropsychological performance but not with severity of motor impairment. Conclusions: N-acetylaspartate reduction in occipital lobes may be a marker for dementia in PD. The distribution of metabolite reduction differs from that reported in Alzheimer disease. These findings suggest that proton spectroscopy may serve as a metabolic marker of cognitive disturbance in patients with PD.
引用
收藏
页码:1415 / 1420
页数:6
相关论文
共 38 条
[1]   Risk of dementia in Parkinson's disease - A community-based, prospective study [J].
Aarsland, D ;
Andersen, K ;
Larsen, JP ;
Lolk, A ;
Nielsen, H ;
Kragh-Sorensen, P .
NEUROLOGY, 2001, 56 (06) :730-736
[2]   Proton magnetic resonance spectroscopy of patients with parkinsonism [J].
Abe, K ;
Terakawa, H ;
Takanashi, M ;
Watanabe, Y ;
Tanaka, H ;
Fujita, N ;
Hirabuki, N ;
Yanagihara, T .
BRAIN RESEARCH BULLETIN, 2000, 52 (06) :589-595
[3]  
[Anonymous], MOVEMENT DISORDERS C
[4]   N-ACETYL-L-ASPARTIC ACID - A LITERATURE-REVIEW OF A COMPOUND PROMINENT IN H-1-NMR SPECTROSCOPIC STUDIES OF BRAIN [J].
BIRKEN, DL ;
OLDENDORF, WH .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1989, 13 (01) :23-31
[5]   PARKINSON DISEASE, DEMENTIA, AND ALZHEIMER-DISEASE - CLINICOPATHOLOGICAL CORRELATIONS [J].
BOLLER, F ;
MIZUTANI, T ;
ROESSMANN, U ;
GAMBETTI, P .
ANNALS OF NEUROLOGY, 1980, 7 (04) :329-335
[6]  
BOWEN BC, 1995, AM J NEURORADIOL, V16, P61
[7]   Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy [J].
Clarke, CE ;
Lowry, M .
EUROPEAN JOURNAL OF NEUROLOGY, 2000, 7 (06) :661-665
[8]  
Daniel S E, 1993, J Neural Transm Suppl, V39, P165
[9]   DIFFERENTIATION OF MULTIPLE SYSTEM ATROPHY FROM IDIOPATHIC PARKINSONS-DISEASE USING PROTON MAGNETIC-RESONANCE SPECTROSCOPY [J].
DAVIE, CA ;
WENNING, GK ;
BARKER, GJ ;
TOFTS, PS ;
KENDALL, BE ;
QUINN, N ;
MCDONALD, WI ;
MARSDEN, CD ;
MILLER, DH .
ANNALS OF NEUROLOGY, 1995, 37 (02) :204-210
[10]   α-Synuclein and the Lewy body disorders [J].
Dickson, DW .
CURRENT OPINION IN NEUROLOGY, 2001, 14 (04) :423-432